

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)
(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

**“VINORELBINE TARTRATE LIPOSOME INJECTION” FOR
THE TREATMENT OF LUNG CANCER WAS
GRANTED CLINICAL TRIAL APPROVAL**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that “Vinorelbine Tartrate Liposome Injection” (the “**Product**”) developed by the Group was recently granted clinical trial approval by the China Food and Drug Administration of the People’s Republic of China (“**China**”) for carrying out clinical trials in China.

Vinorelbine is a vinca-alkaloid oncology drug that features high anti-cancer activity. It can be used alone or in combination with other drugs clinically for the treatment of non-small cell lung cancer, breast cancer, ovarian cancer and malignant lymphoma.

“Vinorelbine Tartrate Liposome” is a liposome product developed by the Group. Significant advantages over the regular preparation have been demonstrated in the pre-clinical studies: the Product can significantly suppress the growth of various solid tumours in a dose-dependent manner, including S180 sarcoma, H22 liver cancer, RM-1 prostate cancer, Lewis lung cancer and H460 human large-cell lung cancer, with efficacy increased by at least four times. Moreover, results of animal safety assessment have shown that the Product has good safety and tolerance.

Currently, there is no product similar to “Vinorelbine Tartrate Liposome Injection” available in the global market. The Product has obtained patents in various countries including China, the U.S., Japan, the United Kingdom, France and Germany. Given the favourable results in the pre-clinical studies, the Group will endeavour to launch the Product as soon as possible.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 16 April 2018

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. WANG Zhenguo, Mr. WANG Jinxu, Mr. LU Hua, Mr. LI Chunlei and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.